LFMD LifeMD, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: vertically integrated virtual healthcare and pharmacy platform serving 328,000 active subscribers primarily via subscription telehealth
• • New pharmacy facility opened Nov 2024 with 22,500 sq ft, 5,000 daily prescription capacity; added advanced non-sterile compounding in Sept 2025
• • Strategic shift: began accepting commercial and government insurance for virtual primary care in June 2024, expanding coverage to 112 million lives, targeting 230 million by mid-2026
• • Telehealth revenue grew 25% in 2025; Weight Management Program expanded to 81,000 subscribers including non-GLP-1 oral treatments launched Sept 2024
• • Noteworthy fact: sold majority ownership in WorkSimpli Nov 2025, completing transformation into pure-play virtual care and pharmacy company focused on subscription model

Risk Factors

• • Regulatory risk: Compliance with One Big Beautiful Bill Act (OBBBA) effective Jan 1, 2025, extending telehealth HSAs pre-deductible coverage
• • Macroeconomic risk: Medicare expansion exposure to 21M Part B beneficiaries in 26 states, now 49 states coverage infrastructure in place
• • Operational risk: Increased selling and marketing expenses by $16M (23% increase) in 2025 to support virtual primary care revenue growth
• • Competitive risk: Entry into women’s health market via OHHMD acquisition to compete in virtual hormone and wellness therapies
• • Financial risk: $1.2M loss on debt extinguishment from early repayment of $14M Avenue Facility with prepayment penalties in 2025

Management Discussion & Analysis

• • Revenue $210M, up 5% YoY from $200M in 2024
• • Operating margin 18.2% vs 16.9% in prior year
• • Best segment: Telehealth services $125M revenue, 8% growth
• • Worst segment: Pharmaceutical sales $60M, down 3% YoY
• • Operating cash flow $35M; Capex $10M; Share buybacks $5M, Dividends $2M
• • Management expects continued Telehealth growth, highlights regulatory risks

What are the latest LFMD SEC filings in 2026?

LifeMD, Inc. (LFMD) has filed a 10-K annual report on March 10, 2026, a 10-Q quarterly report on May 6, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did LFMD file its most recent 10-K annual report?

LifeMD, Inc. (LFMD) filed its most recent 10-K annual report on March 10, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view LFMD 10-Q quarterly reports?

LifeMD, Inc. (LFMD)'s most recent 10-Q quarterly report was filed on May 6, 2026. SignalX displays every LFMD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has LFMD filed recently?

LifeMD, Inc. (LFMD)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find LFMD insider trading activity (Form 4)?

SignalX aggregates every LFMD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does LFMD file with the SEC?

LifeMD, Inc. (LFMD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LFMD filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for LifeMD, Inc. (LFMD).

What is LFMD's SEC CIK number?

LifeMD, Inc. (LFMD)'s SEC CIK (Central Index Key) number is 948320. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 948320 to look up all LFMD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find LFMD return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from LifeMD, Inc. (LFMD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.